<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730544</url>
  </required_header>
  <id_info>
    <org_study_id>NIPISAFE G-106</org_study_id>
    <nct_id>NCT04730544</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer</brief_title>
  <acronym>NIPISAFE</acronym>
  <official_title>Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NIPISAFE is open-label, phase II study, to identify a combination scheme of nivolumab and&#xD;
      ipilimumab with a high level of clinical activity, but with a lower toxicity in MSI/dMMR&#xD;
      Metastatic Colorectal Cancer (mCRC) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events grade 3 or 4</measure>
    <time_frame>At week 24 for two combination schemes</time_frame>
    <description>According to NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>At week 24 for two combination schemes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Assessed up to 80 months</time_frame>
    <description>All grade and severe toxicities, according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>At weeks 24 and 48, and at 2 years</time_frame>
    <description>To assess ORR of two combination schemes (RECIST v1.1),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of two combination schemes according to RECIST v1.1</measure>
    <time_frame>at week 48 and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of two combination schemes according to Immune Response Evaluation Criteria In Solid Tumors (iRECIST)</measure>
    <time_frame>at weeks 24 and 48, and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of two combination schemes (RECIST v1.1),</measure>
    <time_frame>at week 48 and at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who received immune modulating concomitant medication</measure>
    <time_frame>until the end of the study treatment - 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who received hormonal replacement therapy for immune-related endocrine toxicities</measure>
    <time_frame>until the end of the study treatment - 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to onset, median time to resolution (grade 3-4) of Serious adverse event (SAEs) and Treatment-related adverse events (TRAEs),</measure>
    <time_frame>Assessed up to 80 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Health-related quality of life (HRQoL) score definitive deterioration (TUDD)</measure>
    <time_frame>assessed up 48 months</time_frame>
    <description>TUDD is defined as the time interval between randomization and the first occurrence of a decrease in quality of life questionnaire (QLQ)-C30 score ⩾5 points without any further improvement in Quality of life (QoL) score ⩾5 points or any further available QoL data. TUDD will be estimated using the Kaplan-Meier method and the long-rank test. Cox regression analyses will be used to identify HRQoL items influencing TUDD. All analyses will be done on the HRQoL population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>MSI-H Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment for 108 weeks (one cycle = 12 weeks; 9 cycles):&#xD;
Nivolumab 480 mg every 4 weeks (27 infusions) and ipilimumab 1 mg/kg every 6 weeks (18 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction of 12 weeks (one cycle = 3 weeks; 4 cycles):&#xD;
Nivolumab 240 mg and ipilimumab 1 mg/kg every 3 weeks for 4 dosing cycles (4 infusions of nivolumab and ipilimumab), Maintenance of 96 weeks (one cycle = 4 weeks; 24 cycles): Nivolumab 480 mg every 4 weeks for 24 dosing cycles (24 infusions) for a total of 24 months of treatment (or less in case of RECIST progression (PD) or limiting toxicity, whichever occurs first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>480 mg</description>
    <arm_group_label>Experimental Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>1 mg/kg</description>
    <arm_group_label>Control Arm B</arm_group_label>
    <arm_group_label>Experimental Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>induction phase : 240 mg and then maintenance : 480 mg</description>
    <arm_group_label>Control Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated patient informed consent form and willingness to comply with all&#xD;
             study procedures and availability for the study duration,&#xD;
&#xD;
          2. Age ≥ 18 years,&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2,&#xD;
&#xD;
          4. Histologically or cytologically confirmed colorectal adenocarcinoma,&#xD;
&#xD;
          5. Documented advanced or metastatic disease not suitable for complete surgical&#xD;
             resection,&#xD;
&#xD;
          6. At least one measurable lesion as assessed by CT-scan or magnetic resonance imaging&#xD;
             (MRI) according to RECIST v1.1 and feasibility of repeated radiological assessments.&#xD;
             Participants with lesions in a previously irradiated field as the sole site of&#xD;
             measurable disease will be permitted to enroll provided the lesion(s) have&#xD;
             demonstrated clear progression and can be measured accurately,&#xD;
&#xD;
          7. Deficient mismatch repair (dMMR) and/or Microsatellite instability (MSI) tumor status&#xD;
             defined by:&#xD;
&#xD;
               -  Loss of MMR protein expression using immunohistochemistry with four (anti-MLH1,&#xD;
                  anti-MSH2, anti-MSH6, and anti-PMS2) antibodies Nota Bene (NB): if loss of only&#xD;
                  one protein, necessary to have Polymerase Chain Reaction (PCR)&#xD;
&#xD;
               -  and/or ≥ two instable markers by pentaplex polymerase chain reaction (BAT-25,&#xD;
                  BAT-26, NR-21, NR-24, and NR-27), NB: if two instable markers in the pentaplex&#xD;
                  panel, it is required to present confirmation of the dMMR status by&#xD;
                  immunohistochemistry or a comparison of the tumor PCR test with matched normal&#xD;
                  tissue.&#xD;
&#xD;
             NB: Agreement of the Sponsor (GERCOR) is mandatory to include the patient (the&#xD;
             patient's file will be verified to confirm MSI/dMMR status before inclusion [an&#xD;
             anonymized fax] and confirmation of a patient's allocation will be sent by mail to the&#xD;
             Investigator within 24h),&#xD;
&#xD;
          8. No or one prior line of systemic treatment for metastatic disease:&#xD;
&#xD;
               -  No prior systemic treatment; if patient received neoadjuvant/adjuvant therapy&#xD;
                  this therapy should be completed &gt; 6 months prior the diagnosis of metastatic or&#xD;
                  recurrent disease is made,&#xD;
&#xD;
               -  Maximum one prior line of systemic treatment; if patient received one prior line&#xD;
                  of systemic therapy in the metastatic setting and experienced progression or&#xD;
                  patient received neoadjuvant/adjuvant therapy and experienced recurrence within ≤&#xD;
                  6 months after completion of therapy,&#xD;
&#xD;
          9. Availability of a representative tumor specimen for exploratory translational&#xD;
             research; tumor tissue specimens, either formalin-fixed, paraffin-embedded (FFPE)&#xD;
             tissue block or unstained tumor tissue sections (minimum of 30 positively charged&#xD;
             slides) from primary or metastatic site must be submitted to the central laboratory,&#xD;
&#xD;
         10. Adequate hematologic and end-organ function, defined by the following laboratory test&#xD;
             results, obtained within 14 days prior to initiation of study treatment:&#xD;
&#xD;
             - Hematological status: White blood cell &gt; 2000/µL; Neutrophils &gt; 1500/µL; Platelets &gt;&#xD;
             100.000/µL; Hemoglobin &gt; 9.0 g/dL;&#xD;
&#xD;
             - Adequate renal function: Serum creatinine level &lt; 150 µM;&#xD;
&#xD;
             - Adequate liver function: Serum bilirubin ≤ 1.5 x upper normal limit (ULN); Alkaline&#xD;
             phosphatase (ALP) ≤ 3 x ULN; Alanine aminotransferase (ALT) ≤ 3.0 x ULN ; Aspartame&#xD;
             aminotransferase (AST) ≤ 3.0 x ULN; Prothrombin time (PT)/International normalized&#xD;
             ratio (INR) and partial PT (PTT) ≤ 1.5 x ULN unless participants are receiving&#xD;
             anticoagulant therapy and their INR is stable and within the recommended range for the&#xD;
             desired level of anticoagulation,&#xD;
&#xD;
         11. Females of childbearing potential must have negative serum pregnancy test within 7&#xD;
             days before starting study treatment,&#xD;
&#xD;
         12. Women of childbearing potential should use effective contraception during treatment&#xD;
             and 5 months thereafter. Males should use condoms during treatment and 7 months&#xD;
             thereafter,&#xD;
&#xD;
         13. Registration in a national health care system ( &quot;Protection Universelle Maladie&quot;&#xD;
             (PUMa) included).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known brain metastases or leptomeningeal metastases,&#xD;
&#xD;
          2. Persistence of toxicities related to prior chemotherapies grade &gt; 1 (NCI CTCAE v5.0;&#xD;
             except alopecia, fatigue, or peripheral sensory neuropathy, which can be grade 2),&#xD;
&#xD;
          3. Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted&#xD;
             therapy, radiotherapy, immunotherapy),&#xD;
&#xD;
          4. Major surgical procedure within 4 weeks prior to initiation of study treatment,&#xD;
&#xD;
          5. Prior treatment with an anti-PD1, anti-programmed death (PD)-L1, anti-PD-L2,&#xD;
             anti-cytotoxic T-lymphocyte-associated (CTLA)-4 antibody, or any other antibody or&#xD;
             drug specifically targeting T-cell co-stimulation or immune checkpoint pathways,&#xD;
             including prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor&#xD;
             agents,&#xD;
&#xD;
          6. Patients receiving any investigational drug, biological, immunological therapy within&#xD;
             the previous 28 days before study treatment,&#xD;
&#xD;
          7. Impossibility of submitting to the medical follow-up of the study for geographical,&#xD;
             social or psychic reasons,&#xD;
&#xD;
          8. Patients with an active, known or suspected autoimmune disease. Patients with type I&#xD;
             diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders&#xD;
             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to be enrolled,&#xD;
&#xD;
          9. History of interstitial lung disease or pneumonitis,&#xD;
&#xD;
         10. Patients with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt;10 mg daily prednisone or equivalent) or other immunosuppressive medications within&#xD;
             14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid&#xD;
             doses &gt;10 mg daily prednisone or equivalent are permitted in the absence of active&#xD;
             autoimmune disease,&#xD;
&#xD;
         11. Prior malignancy active within the previous 3 years, except for:&#xD;
&#xD;
               -  Locally curable cancers that have been apparently cured (e.g. squamous cell skin&#xD;
                  cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix,&#xD;
                  or breast);&#xD;
&#xD;
               -  Lynch syndrome-related non-colorectal cancer in complete remission for &gt; 1 year;&#xD;
&#xD;
         12. Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg]&#xD;
             test prior to randomization) virus (HBV) or hepatitis C virus (HCV), or human&#xD;
             immunodeficiency virus (HIV) infection. Patients with past HBV infection or resolved&#xD;
             HBV infection (defined as having a negative HBsAg test and a positive antibody to&#xD;
             hepatitis B core antigen antibody test) are eligible. Patients positive for HCV&#xD;
             antibody are eligible only if polymerase chain reaction testing is negative for HCV&#xD;
             ribonucleic acid.&#xD;
&#xD;
         13. Prior allogeneic bone marrow transplantation or prior solid organ transplantation,&#xD;
&#xD;
         14. Any serious or uncontrolled medical disorder that, in the opinion of Investigator, may&#xD;
             increase the risk associated with study participation or study drug administration,&#xD;
             impair the ability of the participant to receive protocol therapy, or interfere with&#xD;
             the interpretation of study results,&#xD;
&#xD;
         15. Known allergy/hypersensitivity to any component of study agents,&#xD;
&#xD;
         16. Administration of a (attenuated) live vaccine within 28 days of planned start of study&#xD;
             therapy of known need for this vaccine during treatment,&#xD;
&#xD;
         17. Patient on tutelage or guardianship or under the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romain COHEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>hôpital Saint Antoine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romain COHEN, MD</last_name>
    <phone>01 40 29 85 00</phone>
    <email>romain.cohen@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Line GARCIA LARNICOL, MD</last_name>
    <phone>01 40 29 85 00</phone>
    <email>marie-line.garcia-larnicol@gercor.com.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clémence TOULLEC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clémence TOULLEC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe BORG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BORG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Philippe METGES</last_name>
    </contact>
    <investigator>
      <last_name>Jean Philippe METGES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe TOURNIGAND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe TOURNIGAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo-Centre jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DUPUIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier DUPUIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Franco-Britannique - Fondation Cognacq-Jay</name>
      <address>
        <city>Levallois-Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoist CHIBAUDEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony TURPIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony TURPIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clélia COUTZAC</last_name>
    </contact>
    <investigator>
      <last_name>Clélia COUTZAC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa CLAVEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Léa CLAVEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laëtitia DAHAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laëtitia DAHAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibault MAZARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thibault MAZARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes- Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaafar BENNOUNA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jaafar BENNOUNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain COHEN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain COHEN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LOUVET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe LOUVET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis SMITH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Denis SMITH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David TOUGERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>David TOUGERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BOUCHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BOUCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - IUCT Rangueil -Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosine GUIMBAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

